We have previously reported that many CD8+ TIL down-regulate CD28 expression after the REP and that these cells became hyporesponsive to re-stimulation with melanoma antigens such as MART-1 and were more susceptible to cell death [8]. The gene discussed is CD28; the disease is melanoma.